{"channel":"misc","content":"https://thehill.com/policy/healthcare/5178180-novo-nordisk-slashes-wegovy-prices/\r\n\r\n<<< Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured and underinsured individuals to be able to pay cash for its weight loss product Wegovy at a significantly reduced cost.\r\nThe drugmaker has named its new program NovoCare\u00ae Pharmacy, which will sell all dose strengths of Wegovy at $499 per month. According to the company, about 90 percent most patients pay a monthly copay of zero to $25 and this new program is aimed at eligible people who are uninsured or are on insurance plans that don\u2019t cover obesity medicines.\r\nThe list price for one month\u2019s supply of Wegovy is $1,349. >>>\r\n\r\nThe lack of first-party payers in the health-care system is a reason why the pricing model is broken beyond repair. (<red> the nature of desperate patients also distorts the medical pricing market)\r\n\r\nThe list price of Wegovy (aka Ozempic) is \"what they want insurance companies to pay a fraction of\".  It is, generally, as high as they can say with a straight face.\r\n\r\nBecause of patents, this does not have to have any relation to the cost of production.  There are various gray-area << compounded semaglutide >> that are effectively the same, but 10x cheaper.\r\n\r\n<xantham> in the future, all the patents will have expired.","created_at":"2025-03-05T22:27:18.327548","id":290,"llm_annotations":{},"parent_id":null,"processed_content":"<p><a href=\"https://thehill.com/policy/healthcare/5178180-novo-nordisk-slashes-wegovy-prices/\" target=\"_blank\" rel=\"noopener noreferrer\">https://thehill.com/policy/healthcare/5178180-novo-nordisk-slashes-wegovy-prices/</a>\r</p>\n<p><div class=\"mlq\"><button type=\"button\" class=\"mlq-collapse\" aria-label=\"Toggle visibility\"><span class=\"mlq-collapse-icon\">\u2212</span></button><div class=\"mlq-content\"><p> Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured and underinsured individuals to be able to pay cash for its weight loss product Wegovy at a significantly reduced cost.\r</p>\n<p>The drugmaker has named its new program NovoCare\u00ae Pharmacy, which will sell all dose strengths of Wegovy at $499 per month. According to the company, about 90 percent most patients pay a monthly copay of zero to $25 and this new program is aimed at eligible people who are uninsured or are on insurance plans that don\u2019t cover obesity medicines.\r</p>\n<p>The list price for one month\u2019s supply of Wegovy is $1,349. </p></div></div>\r</p>\n<p>The lack of first-party payers in the health-care system is a reason why the pricing model is broken beyond repair. <span class=\"colorblock color-red\">\n    <span class=\"sigil\">\ud83d\udca1</span>\n    <span class=\"colortext-content\">( the nature of desperate patients also distorts the medical pricing market)</span>\n  </span>\r</p>\n<p>The list price of Wegovy (aka Ozempic) is \"what they want insurance companies to pay a fraction of\".  It is, generally, as high as they can say with a straight face.\r</p>\n<p>Because of patents, this does not have to have any relation to the cost of production.  There are various gray-area <span class=\"literal-text\">compounded semaglutide</span> that are effectively the same, but 10x cheaper.\r</p>\n<p><span class=\"colorblock color-xantham\">\n    <span class=\"sigil\">\ud83d\udd25</span>\n    <span class=\"colortext-content\"> in the future, all the patents will have expired.</span>\n  </span></p>","quotes":[],"subject":"oh-oh-oh Ozempic!"}